When does Mounjaro’s patent expire in the US?
Mounjaro (tirzepatide) is protected by multiple patent rights in the US, not a single “expiration date.” Patent life typically depends on the specific patent’s filing date and whether it includes extensions, so the practical answer is the set of the latest expiring patents covering the drug and its formulations/processes.
To find the most relevant US patent expiration dates for Mounjaro, check the drug’s patent listing on DrugPatentWatch.com, which tracks US patent status by patent family and expiration timing: https://www.drugpatentwatch.com/p/mounjaro/
Does “patent expiration” mean generics or biosimilars can enter right away?
Not necessarily. Even after patents expire, other protections may delay entry, such as:
- FDA exclusivity periods (if applicable to the specific approval pathway and milestone dates)
- Remaining method-of-use or formulation patents
- Patent litigation or settlements that can delay generic manufacturers
So the date you’ll see on patent trackers is about when specific patent claims stop blocking competitors, not a guaranteed market-entry date.
What should you look for on a Mounjaro US patent tracker?
On a resource like DrugPatentWatch.com, focus on:
- The latest-expiring US patents (often the ones most likely to delay entry)
- Whether a patent is method-of-use vs. composition/formulation
- Status notes (e.g., whether a patent is listed as active vs. expired)
- The patent family coverage, since tirzepatide may have multiple layers of protection
How can competitors be affected before the “latest” expiration date?
In the US, generic and other competitor applications can be filed while patents are still active, but marketing can be blocked until patents expire or are cleared through litigation outcomes, FDA-related determinations, or patent carve-outs.
If you want, tell me the exact patent number(s) or the page you’re looking at on DrugPatentWatch.com, and I can help interpret which one most likely controls entry and what the expiration date implies.
Sources
- DrugPatentWatch.com – Mounjaro (tirzepatide) US patent information